Skip to content

US · CERT · MEDICAL - HEALTHCARE INFORMATION SERVICES

Certara, Inc. (CERT) intrinsic value and stock valuation

$10.55as of 2026-11-21 · Mkt cap 1.25B

Data updated · price as of 2026-11-21

Strongly undervaluedIC value is more than 50% above the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Certara, Inc. DCF and intrinsic value

InvestorsCraft values CERT with the Chepakovich two-stage DCF model — currently rated strongly undervalued. How the model works · Run your own DCF prefilled from CERT’s statements →

Certara, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Medical - Healthcare Information Services Radnor, PA 19087 certara.com

How the business is doing

Fiscal 2018–2025, USD

Revenue
$418.8M+11.5% 5y CAGRd
20182025
Net income
-$-1.59M
20182025
Free cash flow
$69.8M+13.6% 5y CAGRd
20182025
Total equity
$1.06B+5.3% 5y CAGRd
20182025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2018–2025, USD
20252024202320222021
Revenue$418.8M$385.2M$354.3M$335.6M$286.1M
Operating income$21M-$-1.73M-$-40.77M$32.5M$13.6M
Net income-$-1.59M-$-12.05M-$-55.36M$14.7M-$-13.27M
EPSd-$-9.91K-$-75.13K-$-348.31K$92.4K-$-88.56K
Operating cash flow$96.3M$80.5M$82.8M$92.5M$60.4M
Capital expenditure-$-26.56M-$-21.04M-$-15.32M-$-12.53M-$-8.9M
Free cash flow$69.8M$59.4M$67.4M$80M$51.5M
Total assets$1.56B$1.58B$1.56B$1.57B$1.51B
Total debt$11.4M$311.9M$302.6M$308.1M$308.4M
Net debt-$-177.99M$132.7M$67.6M$71.6M$122.6M
Total equity$1.06B$1.06B$1.05B$1.08B$1.04B
Cash and short-term investments$189.4M$179.2M$235M$236.6M$185.8M
Income statement
20252024202320222021
Revenue$418.8M$385.2M$354.3M$335.6M$286.1M
Cost of revenue$161.1M$154.5M$141M$132.6M$111.6M
Gross profit$257.7M$230.6M$213.3M$203.1M$174.5M
Research and development expenses$41M$37.1M$34.2M$28.2M$20.4M
Selling, general and administrative expenses$139.1M$121M$127.4M$99.2M$99.7M
Other expenses$56.6M$74.3M$92.5M$43.2M$40.9M
Operating expenses$236.7M$232.4M$254.1M$170.6M$160.9M
Cost and expenses$397.8M$386.9M$395.1M$303.1M$272.5M
Interest income$0.00$0.00$0.00$0.00$0.00
Interest expense$19.7M$21.5M$22.9M$17.8M$16.8M
Depreciation and amortization$56.6M$68M$56.1M$52.5M$45.1M
Ebitda$83.9M$72.4M$23.8M$89M$58.6M
Operating income$21M-$-1.73M-$-40.77M$32.5M$13.6M
Total other income/expenses, net-$-13.4M-$-15.45M-$-14.37M-$-13.77M-$-16.95M
Income before tax$7.62M-$-17.18M-$-55.14M$18.8M-$-3.38M
Income tax expense$9.21M-$-5.13M$210K$4.02M$9.89M
Net income-$-1.59M-$-12.05M-$-55.36M$14.7M-$-13.27M
Weighted average shares outstanding$160.4M$160.4M$158.9M$156.9M$149.8M
Weighted average diluted shares outstanding$160.4M$160.4M$158.9M$159.4M$149.8M
Balance sheet
20252024202320222021
Cash and short-term investments$189.4M$179.2M$235M$236.6M$185.8M
Net receivables$116.3M$119.1M$93.3M$88.8M$78.3M
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$315.1M$310.9M$340.2M$342.3M$274.7M
Property, plant and equipment, net$13.8M$16M$12.3M$16.8M$15.6M
Goodwill and intangible assets$1.22B$1.24B$1.2B$1.2B$1.22B
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$1.24B$1.26B$1.22B$1.23B$1.24B
Total assets$1.56B$1.58B$1.56B$1.57B$1.51B
Accounts payable$3.43M$3.5M$5.17M$7.53M$7.46M
Short-term debt$2.96M$8.31M$7.39M$8.01M$8.35M
Deferred revenue$75.4M$77.8M$60.7M$52.2M$45.5M
Total current liabilities$153.4M$146.1M$130M$103.2M$92.2M
Long-term debt$8.44M$303.6M$295.2M$300.1M$300M
Deferred revenue, non-current$0.00$1.05M$1.07M$2.81M$1.53M
Total non-current liabilities$340.4M$370.4M$386.3M$390.1M$377.7M
Capital lease obligations$0.00$16.5M$11.3M$15.1M$13.6M
Total liabilities$493.8M$516.5M$516.3M$493.3M$469.9M
Common stock$1.64M$1.62M$1.6M$1.6M$1.6M
Retained earnings-$-129.88M-$-128.28M-$-116.23M-$-60.87M-$-75.6M
Accumulated other comprehensive income (loss)$2.04M-$-13.42M-$-7.59M-$-8.23M-$-3.93M
Total equity$1.06B$1.06B$1.05B$1.08B$1.04B
Total investments$0.00$0.00$0.00$0.00$0.00
Total debt$11.4M$311.9M$302.6M$308.1M$308.4M
Net debt-$-177.99M$132.7M$67.6M$71.6M$122.6M
Cash flow statement
20252024202320222021
Net income-$-1.59M-$-12.05M-$-55.36M$14.7M-$-13.27M
Depreciation and amortization$75.2M$68M$56.1M$52.5M$45.1M
Stock-based compensation$33.1M$34.8M$28.3M$30.3M$29.5M
Change in working capital$910K-$-10.03M-$-4.72M$3.73M-$-2.92M
Accounts receivable$430K-$-16.23M$150K-$-15.01M-$-10.07M
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable$0.00$0.00$0.00$0.00$0.00
Net cash provided by operating activities$96.3M$80.5M$82.8M$92.5M$60.4M
Investments in property, plant and equipment-$-26.56M-$-21.04M-$-15.32M-$-12.53M-$-8.9M
Acquisitions, net$0.00-$-91.33M-$-64.23M-$-15.31M-$-261.02M
Net cash used for investing activities-$-26.56M-$-112.37M-$-79.55M-$-27.84M-$-269.92M
Common stock issued$0.00$0.00$0.00$0.00$133.4M
Common stock repurchased-$-42.61M$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities-$-63.99M-$-21.01M-$-9.45M-$-7.36M$123.4M
Net change in cash$10.2M-$-55.77M-$-4.74M$53.1M-$-86.67M
Cash at end of period$189.4M$179.2M$235M$239.7M$186.6M
Operating cash flow$96.3M$80.5M$82.8M$92.5M$60.4M
Capital expenditure-$-26.56M-$-21.04M-$-15.32M-$-12.53M-$-8.9M
Free cash flow$69.8M$59.4M$67.4M$80M$51.5M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Certara, Inc.

        Certara, Inc. provides advanced software solutions and technology-driven services, specializing in biosimulation throughout the entire drug development lifecycle. From initial drug discovery and preclinical research to clinical trials, regulatory submissions, and market entry, the company's core mission is to accelerate the delivery of new medicines to patients by transforming these processes with its innovative biosimulation software and expertise. Its extensive portfolio of technology-enabled services includes mechanistic and empirical biosimulation, strategic guidance for drug development and regulatory affairs, clinical pharmacology, model-based meta-analysis, specialized regulatory writing and medical communications, regulatory operations support, and market access consultation. Furthermore, Certara offers a robust suite of software platforms covering mechanistic and empirical PK/PD biosimulation, data standardization and compliance, scientific informatics, clinical outcomes databases for biosimulation, authoring and management of regulatory submissions, and market access communication. The company's clientele primarily comprises biopharmaceutical firms, academic institutions, and governmental organizations. Established in 2008 and headquartered in Princeton, New Jersey, Certara maintains a significant global presence, with operations spanning numerous countries including the United States, Canada, Spain, Luxembourg, Portugal, the United Kingdom, Germany, France, the Netherlands, Denmark, Switzerland, Italy, Poland, Japan, the Philippines, India, Australia, and China.

        CEO
        Jon Resnick
        Employees
        1.55K
        Beta
        1.46

        Explore

        Frequently asked questions

        What is the intrinsic value of Certara, Inc. (CERT)?

        Certara, Inc. (CERT) is currently strongly undervalued based on the InvestorsCraft IC model — IC value is more than 50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is CERT undervalued?

        CERT trades at a price of $10.55 (Nov 21, 2026): strongly undervalued — IC value is more than 50% above the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.